Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19

BMC Cardiovasc Disord. 2021 Jul 3;21(1):327. doi: 10.1186/s12872-021-02137-9.

Abstract

Background: The relative association between cardiovascular (CV) risk factors, such as diabetes and hypertension, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear.

Methods: We conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained.

Results: Among 1721 patients (median age 71 years, 57% male), 349 (20.3%) had pre-existing CVD (CVD), 888 (51.6%) had CV risk factors without CVD (RF-CVD), 484 (28.1%) had neither. Patients with CVD were older with a higher burden of non-CV comorbidities. During follow-up, 438 (25.5%) patients died: 37% with CVD, 25.7% with RF-CVD and 16.5% with neither. CVD was independently associated with in-hospital mortality among patients < 70 years of age (adjusted HR 2.43 [95% CI 1.16-5.07]), but not in those ≥ 70 years (aHR 1.14 [95% CI 0.77-1.69]). RF-CVD were not independently associated with mortality in either age group (< 70 y aHR 1.21 [95% CI 0.72-2.01], ≥ 70 y aHR 1.07 [95% CI 0.76-1.52]). Most CV complications occurred in patients with CVD (66%) versus RF-CVD (17%) or neither (11%; p < 0.001). 213 [12.4%] patients developed venous thromboembolism (VTE). CVD was not an independent predictor of VTE.

Conclusions: In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD. CVD-related hazard may be mediated, in part, by new CV complications. Optimal care and vigilance for destabilised CVD are essential in this patient group. Trial registration n/a.

Keywords: COVID-19; Cardiovascular disease; Cardiovascular risk factors; Diabetes; Hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • COVID-19* / mortality
  • COVID-19* / physiopathology
  • COVID-19* / therapy
  • Cardiovascular Diseases* / complications
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / epidemiology
  • Cohort Studies
  • Diabetes Mellitus / epidemiology*
  • Female
  • Heart Disease Risk Factors
  • Hospital Mortality*
  • Humans
  • Hypertension / epidemiology*
  • Male
  • Mortality
  • Outcome and Process Assessment, Health Care
  • Risk Assessment / methods
  • Risk Assessment / statistics & numerical data
  • SARS-CoV-2 / isolation & purification
  • United Kingdom / epidemiology
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / epidemiology
  • Venous Thromboembolism* / etiology